Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a medical technology company focused on peripheral nerve repair, regeneration, and restoration of function. The AXGN news feed on this page aggregates company announcements, earnings releases, regulatory updates, and other disclosures related to its nerve repair portfolio and corporate activities.
Recent Axogen news has highlighted revenue growth, gross margin trends, and updated financial guidance, as well as developments in reimbursement coverage for nerve repair procedures using allografts and synthetic conduits. Earnings releases and accompanying conference calls provide details on revenue by quarter, profitability metrics, cash and investment balances, and management’s commentary on market development and commercial execution across extremities, oral and maxillofacial, head and neck, and breast reconstruction markets.
Regulatory milestones are a key theme in AXGN news. The company has reported FDA acceptance and subsequent approval of its Biologics License Application for Avance (acellular nerve allograft-arwx), including information on the Prescription Drug User Fee Act (PDUFA) review timeline, accelerated approval indications, and anticipated commercial availability under the biologic framework. Updates on professional society position statements and clinical practice guidelines recognizing nerve allograft as a standard medical practice option for peripheral nerve defects also appear in company communications.
Investors and observers can also find notices about Axogen’s participation in healthcare and investor conferences, where management presents the company’s strategy and meets with institutional investors. By following AXGN news here, readers can monitor financial results, regulatory progress, reimbursement developments, and corporate events that shape Axogen’s peripheral nerve repair business over time.
Axogen (NASDAQ: AXGN) will participate in the 2026 Bank of America Global Healthcare Conference and present on Wednesday, May 13, 2026 at 9:35 AM PT. A live audio webcast will be available via the company’s Investors website at ir.axogeninc.com.
Axogen (NASDAQ: AXGN) reported first-quarter 2026 revenue of $61.5M, up 26.6% year-over-year, gross margin of 75.2%, and a net loss of $19.6M (or $0.38 per share). Adjusted net income was $4.1M and adjusted EBITDA was $5.7M. Cash and investments totaled $103.6M on March 31, 2026.
The company raised full-year revenue guidance to at least 20% growth or $270M, expects gross margin of 74–76%, and plans to be free cash flow positive for 2026. Axogen completed an upsized offering and repaid its Oberland loan.
Axogen (Nasdaq: AXGN) will report first quarter 2026 financial results on April 28, 2026. Management will host an investor conference call and webcast at 8:00 a.m. ET after the release.
Investors can join by phone or listen to a live webcast; an archived replay and presentation slides will be available on the company's Investors page at www.axogeninc.com.
Axogen (NASDAQ: AXGN) reported fourth-quarter 2025 revenue of $59.9M (+21.3% YoY) and full-year 2025 revenue of $225.2M (+20.2% YoY). Full-year adjusted EBITDA was $27.9M. FDA approved the BLA for Avance on Dec 3, 2025. Axogen completed a public offering raising $133.3M net and used $69.7M to repay a loan. 2026 guidance: revenue at least 18% growth (~$265.7M), gross margin 74–76%, and expected free cash flow positive for the year.
Axogen (Nasdaq: AXGN) management will participate in three investor conferences in early March 2026: Raymond James (presentation), Leerink Global Healthcare (fireside chat) and Citizens Life Sciences (fireside chat).
Presentations are scheduled March 3, March 9, and March 10, 2026; webcasts and 90-day replays are available via the company's Investors page at www.axogeninc.com.
Axogen (Nasdaq: AXGN) will release fourth quarter and full year 2025 financial results on February 24, 2026. Management will host an investor conference call and webcast at 8:00 a.m. ET following the release.
Investors can join by phone at the provided toll-free or direct dial numbers, and a live webcast, archived replay, and presentation slides will be available on the company Investors page at www.axogeninc.com.
Axogen (Nasdaq: AXGN) priced an upsized underwritten public offering of 4,000,000 common shares at $31.00 per share, generating gross proceeds of about $124 million (assuming no exercise of the option). The underwriters have a 30-day option to buy up to 600,000 additional shares at the public offering price less discounts and commissions. The offering is expected to close on January 23, 2026, subject to customary conditions.
Axogen intends to use net proceeds to pay off and terminate its term loan facility with Oberland Capital, and for working capital, capital expenditures and other general corporate purposes. Wells Fargo Securities and Mizuho lead the deal; Canaccord Genuity and Raymond James are co-managers.
Axogen (Nasdaq: AXGN) announced a proposed underwritten public offering of $85.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $12.75 million of shares. All shares will be sold by Axogen and the offering is subject to market and other conditions with no assurance of completion or final terms. Wells Fargo Securities and Mizuho are lead book-runners; Canaccord Genuity and Raymond James are co-managers. Axogen intends to use net proceeds for early payoff and termination of its Oberland Capital term loan facility, working capital, capital expenditures and general corporate purposes. The offering is being made under an automatic Form S-3ASR registration statement that became effective on January 21, 2026.
Axogen (NASDAQ: AXGN) reported preliminary unaudited results for Q4 and full-year 2025. Q4 revenue is expected to be approximately $59.9 million (+21.3% vs Q4 2024) and full-year revenue is expected to be approximately $225.2 million (+20.2% vs FY 2024). Gross margin is expected to be above 74%, despite approximately $1.9 million of one-time costs tied to the FDA BLA approval of Avance® (67% of those costs are non-cash stock-compensation vesting).
Cash, cash equivalents, restricted cash, and investments are expected to total about $45.5 million as of December 31, 2025, an increase of approximately $6.0 million year-over-year. The company received FDA BLA approval for Avance® on December 3, 2025. Final audited results are expected in late February 2026.
Axogen (NASDAQ: AXGN) will present at the J.P. Morgan 2026 Healthcare Conference. Management is scheduled to present on Thursday, January 15, 2026 at 10:30 AM Pacific Standard Time. A live audio webcast will be available via the company’s investor relations site at ir.axogeninc.com.
This provides investors and analysts an opportunity to hear management commentary on recent developments and strategic priorities directly from company leadership.